help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on February 10, 2005
Endocrinology, doi:10.1210/en.2004-1282
A more recent version of this article appeared on April 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
146/4/1854    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrari, S.
Right arrow Articles by Bouxsein, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrari, S.
Right arrow Articles by Bouxsein, M.

Submitted on September 29, 2004
Accepted on January 3, 2005

Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-arrestin2

SL Ferrari*, DD Pierroz, V Glatt, DS Goddard, EN Bianchi, FT Lin, D Manen, and ML Bouxsein

Service of Bone Diseases, WHO Collaborating Center for Osteoporosis Prevention, Department of Rehabilitation and Geriatrics, Geneva University Hospital, 1211 Geneva 14, Switzerland; Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Cell Biology, University of Alabama, Birmingham, AL 35294, USA

* To whom correspondence should be addressed. E-mail: Serge.Ferrari{at}medecine.unige.ch.

Intermittent PTH administration increases bone turnover, resulting in net anabolic effects on bone. These effects are primarily mediated by intracellular cAMP signaling. However, the molecular mechanisms that regulate PTH activity in bone remain incompletely understood. {beta}-arrestin2, a G protein-coupled receptor regulatory protein, inhibits PTH-stimulated cAMP accumulation in vitro. Using {beta}-arrestin2- (KO) and wild-type (WT) mice, we investigated the response to PTH in primary osteoblasts (POB) and the effects of intermittent PTH administration on bone mass and microarchitecture in vivo. Compared with WT, PTH-stimulated intracellular cAMP was increased and sustained in KO POB. Intermittent exposure of POB to PTH significantly decreased the ratio of osteoprotegerin (OPG) / receptor activator of nuclear factor {kappa}B ligand (RANKL) mRNA expression in KO POB, whereas it increased this ratio in WT POB. Total body bone mass, cortical and trabecular bone parameters were 5-10% lower in male KO mice compared with WT, and these differences were magnified upon in vivo administration of intermittent PTH (80 µg/kg/d) for one month. Thus, PTH significantly increased total body bone mineral content (TB BMC) as well as vertebral trabecular bone volume and thickness in WT, but not KO mice. The anabolic response to PTH in cortical bone was also slightly more pronounced in WT than KO mice. Histomorphometry indicated that PTH prominently stimulated indices of bone formation in both WT and KO mice, whereas it significantly increased indices of bone resorption (i.e. osteoclast number and surface) in KO mice only. In conclusions, these results suggest that {beta}-arrestins may specify the activity of intermittent PTH on the skeleton by limiting PTH-induced osteoclastogenesis.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
L. J. Raggatt, L. Qin, J. Tamasi, S. C. Jefcoat Jr., E. Shimizu, N. Selvamurugan, F. Y. Liew, L. Bevelock, J. H. M. Feyen, and N. C. Partridge
Interleukin-18 Is Regulated by Parathyroid Hormone and Is Required for Its Bone Anabolic Actions
J. Biol. Chem., March 14, 2008; 283(11): 6790 - 6798.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
L. S. H. Nissen-Meyer, R. Jemtland, V. T. Gautvik, M. E. Pedersen, R. Paro, D. Fortunati, D. D. Pierroz, V. A. Stadelmann, S. Reppe, F. P. Reinholt, et al.
Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice
J. Cell Sci., August 15, 2007; 120(16): 2785 - 2795.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. Merciris, C. Marty, C. Collet, M.-C. de Vernejoul, and V. Geoffroy
Overexpression of the Transcriptional Factor Runx2 in Osteoblasts Abolishes the Anabolic Effect of Parathyroid Hormone in Vivo
Am. J. Pathol., May 1, 2007; 170(5): 1676 - 1685.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. B. Kessler and A. M. Delany
Increased Notch 1 Expression and Attenuated Stimulatory G Protein Coupling to Adenylyl Cyclase in Osteonectin-Null Osteoblasts
Endocrinology, April 1, 2007; 148(4): 1666 - 1674.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
E. Schipani, S. Ferrari, N. S. Datta, L. K. McCauley, A. Vignery, T. Bellido, G. J. Strewler, C. H. Turner, Y. Jiang, and E. Seeman
Meeting Report from the 28th Annual Meeting of the American Society for Bone and Mineral Research
IBMS BoneKEy, November 1, 2006; 3(11): 14 - 50.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Gesty-Palmer, M. Chen, E. Reiter, S. Ahn, C. D. Nelson, S. Wang, A. E. Eckhardt, C. L. Cowan, R. F. Spurney, L. M. Luttrell, et al.
Distinct beta-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation
J. Biol. Chem., April 21, 2006; 281(16): 10856 - 10864.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society